RXST
RxSight, Inc. (NASDAQ)
Healthcare — Medical Devices
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Price History
Fundamentals
| Market Cap | $214.02M |
| P/E Ratio (TTM) | - |
| Forward P/E | -9.23 |
| EPS (TTM) | $-1.13 |
| Dividend Yield | - |
| Profit Margin | -36.59% |
| Revenue Growth | -18.50% |
| ROE | -17.06% |
| Debt/Equity | 4.05 |
| Recommendation | None |
| Analyst Target | $8.79 |
| Analysts | 7 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 61.0 |
| Beta | 1.13 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $13.65 |
| 52-Week Low | $4.48 |
| 50-Day Avg | $5.76 |
| 200-Day Avg | $8.19 |
| Avg Volume | 939.7K |
| Volume | $1.73M |
Performance Analysis
NEUTRALRXST presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:30 UTC
Back to Screener Export Report